Summit Therapeutics PLC
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -10.6% | -12.3% | +91.8% | +42.1% | -9.3% | -14.6% | -34.6% | +34.5% | +113.0% | -11.9% | +53.1% | |
| – | -10.9% | -13.4% | +99.7% | +44.0% | -9.5% | -15.2% | -36.2% | +34.5% | +116.9% | -12.5% | +54.1% | |
| – | +189.0% | -13.6% | -54.0% | +218.5% | +17.1% | +95.5% | +8.2% | +34.5% | -29.9% | -51.7% | +419.2% | |
| – | -9.9% | -15.3% | +106.0% | +44.5% | -11.3% | -15.1% | -36.6% | – | – | -14.2% | +52.1% | |
| – | +0.5% | +12.2% | +0.0% | -33.1% | -11.6% | – | – | – | – | – | – | |
| – | -51.9% | -87.0% | – | – | – | – | – | – | – | – | – | |
| – | +0.5% | -0.3% | -0.6% | +2.3% | -1.9% | 0.0% | -0.2% | +34.5% | -25.7% | +0.3% | +32.1% | |
| – | +1.3% | +6.5% | +9.8% | -57.3% | -24.5% | -18.2% | +68.8% | +34.5% | -1.4% | +12.8% | +58.1% | |
| – | -82.7% | +15.6% | +493.1% | -59.3% | -25.9% | -19.0% | +78.7% | +34.5% | -16.6% | +16.6% | +64.0% | |
| – | -97.4% | +32.6% | +2,679.8% | -73.6% | -86.1% | -8.8% | -26.3% | – | – | -4.1% | +47.3% | |
| – | -22.5% | +140.5% | -48.0% | -6.0% | +49.3% | +4.4% | +327.5% | +34.5% | -32.3% | +38.7% | +9.6% | |
| – | +0.0% | +0.0% | – | – | – | – | – | – | – | – | – | |
| – | -24.7% | -42.7% | +337.6% | +116.8% | -7.0% | -14.1% | -46.4% | +34.5% | +154.3% | -15.3% | +52.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.4% | +0.2% | +0.9% | +2.6% | +1.5% | +0.1% | +0.7% | +0.1% | +2.9% | +1.2% | +0.4% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.